Saturday, July 21, 2018 10:50:25 AM
Everyone is probably aware from the new of the increasing opioid epidemic here in the US, however prescription drug abuse is also a serious and growing problem in the United States. In the US alone, an estimated 54 million people over the age of 12 have used prescription drugs for nonmedical reasons.
This study which was conducted by the Fraunhofer Institute in Rostock Germany last year was published and recently uploaded, shows how Cytosorb can also help in the removal of some of these agents. Frauhofer has been one of the key study centers for Cytosorb for the last several years.
http://cytosorb-therapy.com/wp-content/uploads/2018/02/2017_Koertge_Poster_ESAO.pdf
Results:
Considerable removal of amitriptyline, diazepam, digoxin, quetiapine, and rivaroxaban was observed: 87.7 to 96.9 % of these administered drugs was rapidly removed from the blood, predominantly within 30 to 60 min of hemoperfusion, resulting in plasma levels near, within or below the respective therapeutic concentration range.
Paracetamol, ibuprofen, and amiodarone plasma concentrations were only decreased to a limited extent with 13.5, 45.4-59.5, and 50.2% removed mass, respectively. A decrease to and below the respective therapeutic concentration range could not be achieved for these substances.
Recent CTSO News
- CytoSorbents Submits Health Canada Medical Device License Application for DrugSorb-ATR Following MDSAP Certification • GlobeNewswire Inc. • 11/04/2024 12:00:00 PM
- FDA Accepts DrugSorb-ATR De Novo Application To Reduce the Severity of CABG-Related Bleeding Due to Ticagrelor and Initiates Substantive Review • GlobeNewswire Inc. • 10/22/2024 11:00:00 AM
- CytoSorbents to Report Third Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 10/17/2024 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 01:00:46 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/09/2024 01:00:14 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 09:25:15 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 10/01/2024 09:22:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/01/2024 12:06:10 PM
- CytoSorbents Submits DrugSorb-ATR Marketing Application to U.S. FDA to Reduce the Severity of Bleeding in Heart Bypass Surgery Patients on the Blood Thinner Ticagrelor and Provides Business Update • GlobeNewswire Inc. • 10/01/2024 11:00:00 AM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 10/01/2024 04:15:18 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 09/26/2024 09:05:05 PM
- CytoSorbents to Present at the H.C. Wainwright 26ᵗʰ Annual Global Investment Conference • GlobeNewswire Inc. • 08/27/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/20/2024 08:51:51 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:58:42 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 08/16/2024 10:57:45 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 08/16/2024 09:28:33 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/16/2024 09:12:04 PM
- CytoSorbents Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • GlobeNewswire Inc. • 08/16/2024 08:05:00 PM
- CytoSorbents Reports Second Quarter 2024 Financial and Operational Results • GlobeNewswire Inc. • 08/13/2024 08:19:55 PM
- CytoSorbents Appoints Peter J. Mariani Chief Financial Officer • GlobeNewswire Inc. • 08/13/2024 08:18:28 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/13/2024 08:04:32 PM
- CytoSorbents to Report Second Quarter 2024 Operating and Financial Results • GlobeNewswire Inc. • 08/07/2024 11:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/01/2024 08:12:56 PM
- CytoSorbents Announces Compliance with Nasdaq Minimum Bid Price Requirement • GlobeNewswire Inc. • 08/01/2024 11:00:00 AM
- CytoSorbents Unveils Newly Redesigned, Unified Company and Product Website • GlobeNewswire Inc. • 07/29/2024 12:00:00 PM
FEATURED SMX and FinGo Enter Into Collaboration Mandate to Develop a Joint 'Physical to Digital' Platform Service • Nov 7, 2024 8:48 AM
FEATURED SBC Medical Group Holdings and MEDIROM Healthcare Technologies Announce Business Alliance • Nov 7, 2024 7:00 AM
Rainmaker Worldwide Inc. (OTC: RAKR) Announces Successful Implementation of 1.6 Million Liter Per Day Wastewater Treatment Project in Iraq • RAKR • Nov 7, 2024 8:30 AM
VAYK Confirms Insider Buying at Open Market • VAYK • Nov 5, 2024 10:40 AM
Rainmaker Worldwide Inc. Announces Strategic Partnership Between Miranda Water Technologies and Fleming College • RAKR • Nov 4, 2024 12:03 PM
North Bay Resources Announces Assays up to 9.5% Copper at Murex Copper Project, British Columbia • NBRI • Nov 4, 2024 9:00 AM